Evidence map›Paper›PMID 42541544›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Effect of neoadjuvant chemotherapy on [

Ayça Arçay Öztürk, Gabriel Liberale, Jean Christophe Noël, Wendy Delbart, Anne-Leen Deleu, Erwin Woff, Raluca Poenaru, Laura Polastro, Laurent Theunissen, Paulus Kristanto and 4 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06061874 (Ga68-labeled Fibroblast Activation Protein Inhibitor-46), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06061874 narecruitingnot on this map

Ga68-labeled Fibroblast Activation Protein Inhibitor-46 (Ga68-FAPI-46) PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis

TypeinterventionalSponsorJules Bordet InstituteRan2023 to 2025Enrolled80ConditionsCancer, Peritoneal CarcinomatosisArmsFAPI PET/CT
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ayça Arçay ÖztürkDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brussels, 1070, Belgium. ayca.arcayozturk@hubruxelles.be.ORCID http://orcid.org/0000-0001-6020-1398
Gabriel LiberaleDepartment of Digestive Surgery and Digestive Surgical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Jean Christophe NoëlDepartment of Pathology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Wendy DelbartATheNO Laboratory, Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Anne-Leen DeleuDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brussels, 1070, Belgium.
Erwin WoffDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brussels, 1070, Belgium.
Raluca PoenaruDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brussels, 1070, Belgium.
Laura PolastroDepartment of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Laurent TheunissenATheNO Laboratory, Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Paulus KristantoClinical Biostatistics Unit, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Sigrid VercauterenDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brussels, 1070, Belgium.
Clementine MarinDepartment of Medical Physics, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Loubna TarajiDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brussels, 1070, Belgium.
Patrick FlamenDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Rue Meylemeersch 90, Brussels, 1070, Belgium.

Funding

L'Association Jules Bordet L'Association Jules Bordet
6 · The paper itself

Abstract

purposeTo evaluate whether [

methodsThis exploratory translational sub-cohort analysis was conducted within the prospective phase II FAPeCa trial (NCT06061874) recruiting patients with colorectal or ovarian cancer with known/suspected PC. Patients who received recent chemotherapy were included in the current analysis. PET parameters, including SUVmax, peritoneal tumour volume (PTV), and total lesion uptake (TLF/TLG) were analysed both on FAPI and [

resultsTwenty-seven patients were included, predominantly with ovarian cancer (26/27), including 10 with paired pre-/post-NAC imaging. All paired FAPI PET parameters declined significantly after NAC. The magnitude of change in paired FAPI PET parameters correlated strongly with pCRS, particularly for SUVmax (ρ=0.866, p=0.005), PTV(2.5) (ρ=0.830, p=0.011), and TLF(2.5) (ρ=0.830, p=0.011), whereas FDG PET parameters and FAPI PTV(40) and TLF(40) showed no significant correlation with pCRS. Changes in FAPI PET parameters also correlated with the CA-125 change. Across the post-NAC cohort, FAPI PET volumetric parameters differed significantly across pCRS categories. Paired IHC demonstrated a significant reduction in FAP expression after NAC, and segment-level FAP IHC score showed a significant moderate correlation with FAPI uptake (SUVmax ρ=0.467, p=0.012; SUVmean ρ=0.554, p=0.005).

conclusions[

Indexed as

FAPI PETNeoadjuvant chemotherapyOvarian cancerPeritoneal carcinomatosisResponse assessment

Identifiers

PMID42541544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.